Newly designed CRRT membranes for sepsis and SIRS-a pragmatic approach for bedside intensivists summarizing the more recent advances: A systematic structured review

ASAIO Journal

Volumn 59, Issue 2, 2013, Pages 99-106

  Honore, Patrick M ^a   Jacobs, Rita ^a   Joannes Boyau, Olivier ^b   De Regt, Jouke ^a   De Waele, Elisabeth ^a   Van Gorp, Viola ^a   Boer, Willem ^c   Verfaillie, Lies ^c   Spapen, Herbert D ^b  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c DEPARTMENT OF CARDIOLOGY   (Belgium)

Author keywords

acute kidney injury; adsorption; dialysis; hemofiltration; ICU; membranes; review; sepsis; septic shock; SIRS; sorbents

Indexed keywords

ACUTE KIDNEY INJURY; HEMOFILTRATION; ICU; SEPSIS; SEPTIC SHOCKS; SIRS;

ADSORPTION; DIALYSIS; INTENSIVE CARE UNITS; MEMBRANES; REVIEWS; SORBENTS;

DIALYSIS MEMBRANES;

ENDOTOXIN; HIGH MOBILITY GROUP B1 PROTEIN; POLY(METHYL METHACRYLATE); POLYACRYLONITRILE; POLYMYXIN B; ACRYLIC ACID RESIN;

ACUTE KIDNEY FAILURE; ADSORPTION; APHERESIS; CONTINUOUS HEMODIALYSIS; CONTINUOUS RENAL REPLACEMENT THERAPY; HEMOPERFUSION; HUMAN; INTENSIVIST; MOLECULAR WEIGHT; PLASMAPHERESIS; POROSITY; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ARTIFICIAL MEMBRANE; RENAL REPLACEMENT THERAPY;

ACRYLIC RESINS; HUMANS; MEMBRANES, ARTIFICIAL; POLYMETHYL METHACRYLATE; RENAL REPLACEMENT THERAPY; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84874883874     PISSN: 10582916     EISSN: 1538943X     Source Type: Journal    
DOI: 10.1097/MAT.0b013e3182816a75     Document Type: Review

References (56)

1. Palewsky PM, Zhang JH, O'Connor TZ, et al; the VA/NIH Acute Renal Failure Trial Network: Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 359: 7-20, 2008.
2. Bellomo R, Cass A, Cole L, et al; for the RENAL Replacement Therapy Study Investigators: Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 361: 1627-1638, 2009.
3. Morgera S, Haase M, Kuss T, et al: Pilot study on the effects of high cutoff hemofltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med 34: 2099-2104, 2006.
4. Yumoto M, Nishida O, Moriyama K, et al: In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofltration. Ther Apher Dial 15: 385-393, 2011.
5. Thomas M, Moriyama K, Ledebo I: AN69: evolution of the world's frst high permeability membrane. Contrib Nephrol 173: 119-129, 2011.
6. Cruz DN, Antonelli M, Fumagalli R, et al: Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301: 2445-2452, 2009.
7. Yaroustovsky M, Abramyan M, Popok Z, et al: Preliminary report regarding the use of selective sorbents in complex cardiac surgery patients with extensive sepsis and prolonged intensive care stay. Blood Purif 28: 227-233, 2009.
8. Honore PM, Clark W: Novel therapeutical concepts for extracorporealtreatment of hyperinfammation and sepsis: immuno-modulation. approach with a novel high Cut-OFF membrane: the SepteX membrane. Proceedings of 10th Congress of World Federation of CCU (WFSICCM). Florence, Italy, 2009.
9. Honoré PM, Jacobs R, Boer W, et al: New insights regarding rationale, therapeutic target and dose of hemofltration and hybrid therapies in septic acute kidney injury. Blood Purif 33: 44-51, 2012.
10. Naka T, Haase M, Bellomo R: 'Super high-fux' or 'high cut-off' hemofltration and hemodialysis. Contrib Nephrol 166: 181-189, 2010.
11. Lee WC, Uchino S, Fealy N, et al: Super high fux hemodialysis at high dialysate fows: an ex vivo assessment. Int J Artif Organs 27: 24-28, 2004.
12. Naka T, Jones D, Baldwin I, et al: Myoglobin clearance by super high-fux hemofltration in a case of severe rhabdomyolysis: a case report. Crit Care 9: R90-R95, 2005.
13. Premru V, Kovac J, Buturovic-Ponikvar J, Ponikvar R: High cut-off membrane hemodiafltration in myoglobinuric acute renal failure: a case series. Ther Apher Dial 15: 287-291, 2011.
14. Stollwerck PL, Namdar T, Stang FH, Lange T, Mailänder P, Siemers F: Rhabdomyolysis and acute renal failure in severely burned patients. Burns 37: 240-248, 2011.
15. Honore PM, Jacobs R, Joannes-Boyau O, et al: Septic AKI in ICU patients. diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developments. Ann Intensive Care 1: 32, 2011.
16. Akizawa T, Koshikawa S, Nakazawa R, Yoshida T, Kaneko M, Nitadori Y: Elimination of beta 2-microglobulin by a new poly-acrylonitrile membrane dialyser: mechanism and physiokinet-ics. Nephrol Dial Transplant 4: 356-365, 1989.
17. Honoré PM, Joannes-Boyau O, Collin V, Boer W, Jennes S: Continuous hemofltration in 2009: what is new for clinicians regarding pathophysiology, preferred technique and recommended dose? Blood Purif 28: 135-143, 2009.
18. Abe T, Kato K, Fujioka T, Akizawa T: The blood compatibilities of blood purifcation membranes and other materials developed in Japan. Int J Biomater2011 Sep 28
19. Rogiers P, Zhang H, Pauwels D, Vincent JL: Comparison of polyacrylonitrile (AN69) and polysulphone membrane during hemofltration in canine endotoxic shock. Crit Care Med 31: 1219-1225, 2003.
20. Hu D, Sun S, Zhu B, et al: Effects of coupled plasma fltration adsorption on septic patients with multiple organ dysfunction syndrome. Ren Fail 34: 834-839, 2012.
21. Honore PM, Joannes-Boyau O, Collin V, Boer W, Gressens B, Janvier G: Practical daily management of extra-renal continuous removal. Reanimation 17: 472-478, 2008.
22. Hirayama Y, Oda S, Wakabayashi K, et al: Comparison of interleukin-6 removal properties among hemoflters consisting of varying membrane materials and surface areas: an in vitro study. Blood Purif 31: 18-25, 2011.
23. Honoré PM, Joannes-Boyau O, Gressens B: CRRT technology and logistics: is there a role for a medical emergency team in CRRT? Contrib Nephrol 156: 354-364, 2007.
24. Nakada TA, Oda S, Matsuda K, et al: Continuous hemodiafltration with PMMA Hemoflter in the treatment of patients with septic shock. Mol Med 14: 257-263, 2008.
25. Yamashita AC, Tomisawa N: Membrane materials for blood purifcation in critical care. Contrib Nephrol 166: 112-118, 2010.
26. Davies B, Cohen J: Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis 11: 65-71, 2011.
27. Joannes-Boyau O, Honore PM, Boer W, Collin V: Are the synergistic effects of high-volume haemofltration and enhanced adsorption the missing key in sepsis modulation? Nephrol Dial Transplant 24: 354-357, 2009.
28. Bosch T: Recent advances in therapeutic apheresis. J Artif Organs 6: 1-8, 2003.
29. Rimmelé T, Assadi A, Cattenoz M, et al: High-volume haemofltration with a new haemofltration membrane having enhanced adsorption properties in septic pigs. Nephrol Dial Transplant 24: 421-427, 2009.
30. Hirasawa H: Indications for blood purifcation in critical care. Contrib Nephrol 166: 21-30, 2010.
31. Sakai Y: Polymethylmethacrylate membrane with a series of serendipity. Contrib Nephrol 173: 137-147, 2011.
32. Nakamura M, Oda S, Sadahiro T, et al: Treatment of severe sepsis and septic shock by CHDF using a PMMA membrane hemofl-ter as a cytokine modulator. Contrib Nephrol 166: 73-82, 2010.
33. Cruz DN, Perazella MA, Bellomo R, et al: Effectiveness of polymyxin B-immobilized fber column in sepsis: a systematic review. Crit Care 11: R 47, 2007. Review.
34. Cantaluppi V, Assenzio B, Pasero D, et al: Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. J Am Soc Nephrol 19: 1904-1918, 2008.
35. Vincent JL: Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA 302: 1968-1969, 2009.
36. Ruberto F, Pugliese F, D'Alio A, et al: Clinical effects of direct hemoperfusion using a polymyxin-B immobilized column in solid organ transplanted patients with signs of severe sepsis and septic shock. A pilot study. Int J Artif Organs 30: 915-922, 2007.
37. Taniguchi T: Cytokine adsorbing columns. Contrib Nephrol 166: 134-141, 2010.
38. Peng ZY, Carter MJ, Kellum JA: Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med 36: 1573-1577, 2008.
39. Kellum JA, Song M, Venkataraman R: Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 32: 801-805, 2004.
40. Quintel M: CytoSorb™ whole blood cytokine adsorption-results of a controlled randomized trial. Presented at the 32nd International Symposium on Intensive Care and Emergency Medicine; March 20-23, 2012; Brussels, Belgium.
41. Kobe Y, Oda S, Matsuda K, Nakamura M, Hirasawa H: Direct hemoperfusion with a cytokine-adsorbing device for the treatment of persistent or severe hypercytokinemia: a pilot study. Blood Purif 25: 446-453, 2007.
42. Bosch T: Therapeutic apheresis-state of the art in the year 2005. Ther Apher Dial 9: 459-468, 2005.
43. Mugnier B, Poullin P, Lefevre P, Roudier J: Clinical improvement in a patient with severe rheumatoid arthritis and chronic hepatitis B after prosorba column immunoadsorption: a one-year fol-lowup. Arthritis Rheum 49: 722-723, 2003.
44. Mattsby-Baltzer I, Bergstrom T, McCrea K, Ward R, Adolfsson L, Larm O: Affnity apheresis for treatment of bacteremia caused by Staphylococcus aureus and/or methicillin-resistant S. aureus (MRSA). J Microbiol Biotechnol 21: 659-664, 2011.
45. Sato H, Yamagata Y, Kidoka T: Studies on quantative levels of complement activation induced by immobilized and soluble forms of protein A: relevance to extracorporal immunoadsorption. Trans Sci 12: 299-305, 1991.
46. Suda K, Takeuchi H, Hagiwara T, et al: Spherical sulfated cellulose adsorbs high-mobility-group box chromosomal protein 1 in vitro and in vivo. ASAIO J 56: 210-214, 2010.
47. Sirolli V, Ballone E, Di Stante S, Amoroso L, Bonomini M: Cell activation and cellular-cellular interactions during hemodialy-sis: effect of dialyzer membrane. Int J Artif Organs 25: 529-537, 2002.
48. Harig F, Feyrer R, Mahmoud FO, Blum U, von der Emde J: Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin. Thorac Cardiovasc Surg 47: 111-118, 1999.
49. Désormeaux A, Moreau ME, Lepage Y, Chanard J, Adam A: The effect of electronegativity and angiotensin-converting enzyme inhibition on the kinin-forming capacity of polyacrylonitrile dialysis membranes. Biomaterials 29: 1139-1146, 2008.
50. Honoré PM, Joannes-Boyau O, Gressens B: Blood and plasma treatments: high-volume hemofltration-a global view. Contrib Nephrol 156: 371-386, 2007.
51. Jacobs R, Honore PM, Joannes-Boyau O, et al: Septic acute kidney injury: the culprit is infammatory apoptosis rather than isch-emic necrosis. Blood Purif 32: 262-265, 2011.
52. Bellomo R, Palevsky PM, Honore PM, et al: Recent trials in critical care nephrology. Contrib Nephrol 165: 299-309, 2010.
53. Honore PM, Jacobs R, Joannes-Boyau O, Spapen HS: Humoral mediator removal with continuous hemofltration in sepsis: treatment:present status and future perspectives. Journal of Japan Society for Blood Purifcation in Critical Care 9: 33-35, 2011.
54. Mitaka C, Tomita M: Polymyxin B-immobilized fber column hemoperfusion therapy for septic shock. Shock 36: 332-338, 2011.
55. Tsuchida K, Yoshimura R, Nakatani T, Takemoto Y: Blood purifcation for critical illness: cytokines adsorption therapy. Ther Apher Dial 10: 25-31, 2006.
56. Matsumura Y, Oda S, Sadahiro T, et al: Treatment of septic shock with continuous HDF using 2 PMMA hemoflters for enhanced intensity. Int J Artif Organs 35: 3-14, 2012.